Company Overview and News

 
Abiomed to Showcase Expanded FDA Indications and Next Generation Heart Recovery Products at TCT 2018

2018-09-19 globenewswire
DANVERS, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), the leader in heart recovery, announces its initiatives at the 30th Transcatheter Cardiovascular Therapeutics (TCT) conference will highlight the recently expanded FDA indications for high-risk PCI and cardiogenic shock. Initiatives will also highlight Protected PCI’s ability to allow for more complete revascularization, which improves outcomes1 and quality of life2,3.
ABMD

13
Health care ETF surges toward record in a broad sector rally

2018-09-18 marketwatch
The SPDR Health Care Select Sector ETF XLV, +0.68% rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average DJIA, +0.86% components, Pfizer Inc.'s stock PFE, +1.22% shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson JNJ, +0.
PFZ ABBV ABMD 500680 UNH PFE PFIZER ABBV

6
Monday’s Biggest Winners and Losers in the S&P 500

2018-09-17 247wallst
September 17, 2018: The S&P 500 closed down 0.6% at 2,888.95. The DJIA also closed down 0.4% at 26,062.02. Separately, the Nasdaq was down 1.4% at 7,895.79.
FTRPR ABMD FTR

46
7 Tech Stocks Sporting Amazon-Like Growth

2018-09-13 investorplace - 1
There’s no doubt that we continue to be in a growth-fueled market. This hasn’t always been the case. In case you’ve forgotten, after the financial meltdown, it was dividend stocks that were the ‘new’ growth stocks. Everyone was scrambling for dividends, and not surprisingly, many stocks began to offer tantalizing dividends.
AMZN TPIC CTRL SNE ABMD SNEJF TNET

35
5 Medical Device Stocks With Impressive Staying Power

2018-09-13 investorplace
Easily the biggest trend in investing has to be healthcare stocks. From rising and aging populations in the developed world to new middle-class consumers gaining access to healthcare for the first time in emerging markets, healthcare demand is only getting bigger by the day. And there’s plenty of ways to play the mega-trend. However, medical device stocks could be the best.
NVCR BSX BDX ISRG ABMD MZOR MDT

1
ABMD / ABIOMED, Inc. / VANGUARD GROUP INC - null (Passive Investment)

2018-09-10 sec.gov - 1
abiomedinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
ABMD

 
ABMD / ABIOMED, Inc. / VANGUARD GROUP INC - null (Passive Investment)

2018-09-10 sec.gov
abiomedinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
ABMD

 
ABMD / ABIOMED, Inc. S-8

2018-09-07 sec.gov
abmd-s8.htm As filed with the Securities and Exchange Commission on September 7, 2018 Registration No. 333-
ABMD

2
Here's Why You Should Hold on to Abiomed (ABMD) for Now

2018-09-04 zacks
Abiomed, Inc. (ABMD - Free Report) is currently one of the top-performing stocks in the MedTech space. The company has a market capitalization of approximately $18.34 billion. The company has continued to gain from its flagship Impella product line but the gross margin remains under pressure.
MASI ISRG ABMD ATHN

25
AMD short sellers gutted by ‘stealthy short squeeze’

2018-08-27 marketwatch
AMD’s S&P-leading stock gain in 2018 has cost shorts nearly $3 billion on paper so far, analyst says
AMD NFLX NVDA ABMD INTC

5
Popular health-care ETF finishes at an all-time high as stock market rallies

2018-08-25 marketwatch
A popular exchange-traded fund that tracks the health-care sector finished at its highest level in its history on Friday. The Health Care Select Sector SPDR ETF XLV, +0.48% advanced by 0.4% to reach 91.82, representing its highest level since the vehicle was created in 1998 to match the S&P 500 index's SPX, +0.62% health-care sector. The record for the health-care ETF underscores a rally on Wall Street in late August that has the small-capitalization Russell 2000 index RUT, +0.
ALGN ABMD ILMN UNH

2
RTIX or ABMD: Which Is the Better Value Stock Right Now?

2018-08-24 zacks
Investors interested in stocks from the Medical - Instruments sector have probably already heard of RTI Surgical (RTIX - Free Report) and Abiomed (ABMD - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
ABMD RTIX

1
Is ICU Medical A Better Bet Than ABIOMED?

2018-08-23 seekingalpha - 1
The tradeoffs here are between near-term upside price gains (green horizontal scale) seen worth protecting against by Market-makers with short positions in each of the stocks, and the prior actual price drawdowns experienced during holdings of those stocks (red vertical scale). Both scales are of percent change from zero to 25%.
ICUI ABMD

44
Best And Worst S&P 500 Stocks On The Road To Nowhere

2018-08-22 seekingalpha - 1
Many are out making a big deal about the fact that the S&P 500 traded back to a new all-time high on Tuesday, but the reality is that the S&P 500 has been "dead money" for nearly seven months now. Along with the index itself being unchanged since late January, a very slight majority of stocks (256) in the S&P are lower now than they were on 1/26, and overall, the average change of the 500 individual stocks in the index since then is a decline of 0.
UA AMZN TWTR UAA XL XLGLF LB ABMD COTY CMG

116
18 High-Growth Stocks With Massive Upside Ahead

2018-08-15 investorplace - 8
This has been a market that favors high-growth stocks and not value plays. Obviously, the rising tide of the nine-year-plus bull market has lifted value boats as well. But clearly, the market of late has prioritized revenue growth over profit growth, to the point that many longtime value investors are in something close to despair.
JD GOOS FB DWCH FIT BZUN CUTR WDAY IRBT NFLX FIZZ WMT ADBE AMZN AGN LULU KO HOLX VFC SQ SHOP KDP DATA ISRG LOGI AYX MDT GPRO BABA ZLTQ PEP GOOGL VEEV ROKU ARLO MSFT ABMD NTGR

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ABMD / ABIOMED, Inc. on message board site Silicon Investor.

ABMD - Replacement Heart System ABMD - Replacement Heart System ABMD - Replacement Heart System ABIOMED --an under valued small co. ABIOMED --an under valued small co. ABIOMED --an under valued small co.
CUSIP: 003654100